Cariprazine long-acting injection (Mapi Pharma) vs JX11502MA
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline
Cariprazine long-acting injection (Mapi Pharma)
Developed by Mapi Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07185815 (registry estimate)
No aligned efficacy figure on record for this race.
JX11502MA
Developed by Zhejiang Jingxin Pharmaceutical Co., Ltd.
NCT06356389 · Phase 1/2 · completed
The study randomized 60 participants to JX11502MA or placebo and used double blinding, but the registry does not report whether the primary safety endpoint was met. Because the results are unavailable, the evidence supports only a limited assessment rather than a definitive conclusion. Its registered primary outcome on ClinicalTrials.gov is "Incidence of treatment-emergent adverse events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
The incidence rate of adverse reactions (Day(1)-Day(7)): JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
Result source: NCT05233657
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cariprazine long-acting injection (Mapi Pharma) | JX11502MA |
|---|---|---|
| PANSS total, change | —Not reported | —Not reported |
| CGI-S, change | —Not reported | —Not reported |
| PANSS response | —Not reported | —Not reported |
| PSP, change | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
PANSS total, change
- Cariprazine long-acting injection (Mapi Pharma)
- —Not reported
- JX11502MA
- —Not reported
CGI-S, change
- Cariprazine long-acting injection (Mapi Pharma)
- —Not reported
- JX11502MA
- —Not reported
PANSS response
- Cariprazine long-acting injection (Mapi Pharma)
- —Not reported
- JX11502MA
- —Not reported
PSP, change
- Cariprazine long-acting injection (Mapi Pharma)
- —Not reported
- JX11502MA
- —Not reported
Relapse (% of patients)
- Cariprazine long-acting injection (Mapi Pharma)
- —Not reported
- JX11502MA
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cariprazine long-acting injection (Mapi Pharma): no structured comparison results are available for Schizophrenia.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine long-acting injection (Mapi Pharma)'s landscape · JX11502MA's landscape